309 related articles for article (PubMed ID: 17661720)
21. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
[TBL] [Abstract][Full Text] [Related]
22. [Screening for prostate cancer: role of PSA in 2006].
Roumeguère T; Peltier A
Rev Med Brux; 2006 Sep; 27(4):S225-31. PubMed ID: 17091883
[TBL] [Abstract][Full Text] [Related]
23. Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer.
Payne H; Cornford P
Urol Oncol; 2011; 29(6):593-601. PubMed ID: 20060331
[TBL] [Abstract][Full Text] [Related]
24. Biomarkers for early prostate cancer detection.
Margreiter M; Stangelberger A; Valimberti E; Herwig R; Djavan B
Minerva Urol Nefrol; 2008 Mar; 60(1):51-60. PubMed ID: 18427435
[TBL] [Abstract][Full Text] [Related]
25. The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers.
Kehinde EO; Maghrebi MA; Anim JT
Can J Urol; 2008 Apr; 15(2):3967-74. PubMed ID: 18405443
[TBL] [Abstract][Full Text] [Related]
26. [Prostatic specific antigen: role and significance in urologic practice].
Manolović D; Pejcić T; Milović N
Srp Arh Celok Lek; 1994; 122(5-6):171-3. PubMed ID: 17977420
[TBL] [Abstract][Full Text] [Related]
27. Psychological distress and prostate specific antigen levels in men with and without prostate cancer.
Turner EL; Lane JA; Metcalfe C; Down L; Donovan JL; Hamdy F; Neal D; Vedhara K
Brain Behav Immun; 2009 Nov; 23(8):1073-8. PubMed ID: 19486654
[TBL] [Abstract][Full Text] [Related]
28. Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen.
Fradet Y
Curr Opin Urol; 2009 May; 19(3):243-6. PubMed ID: 19325493
[TBL] [Abstract][Full Text] [Related]
29. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers.
Sardana G; Jung K; Stephan C; Diamandis EP
J Proteome Res; 2008 Aug; 7(8):3329-38. PubMed ID: 18578523
[TBL] [Abstract][Full Text] [Related]
30. Other biomarkers for detecting prostate cancer.
Nogueira L; Corradi R; Eastham JA
BJU Int; 2010 Jan; 105(2):166-9. PubMed ID: 19930175
[TBL] [Abstract][Full Text] [Related]
31. [Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients].
Leibovitch I; Pinthus Y; Sella BA; Ramon J
Harefuah; 2006 Jan; 145(1):25-9, 78. PubMed ID: 16450720
[TBL] [Abstract][Full Text] [Related]
32. Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer.
Bradford TJ; Wang X; Chinnaiyan AM
Urol Oncol; 2006; 24(3):237-42. PubMed ID: 16678056
[TBL] [Abstract][Full Text] [Related]
33. Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA?
Connolly D; Black A; Murray LJ; Nambirajan T; Keane PF; Gavin A
Prostate Cancer Prostatic Dis; 2009; 12(1):47-51. PubMed ID: 18762815
[TBL] [Abstract][Full Text] [Related]
34. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics.
Schröder FH; Carter HB; Wolters T; van den Bergh RC; Gosselaar C; Bangma CH; Roobol MJ
Eur Urol; 2008 Mar; 53(3):468-77. PubMed ID: 17997011
[TBL] [Abstract][Full Text] [Related]
35. Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials.
Collette L
Eur Urol; 2008 Jan; 53(1):6-9. PubMed ID: 17764823
[No Abstract] [Full Text] [Related]
36. Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project.
van Gils MP; Stenman UH; Schalken JA; Schröder FH; Luider TM; Lilja H; Bjartell A; Hamdy FC; Pettersson KS; Bischoff R; Takalo H; Nilsson O; Mulders PF; Bangma CH
Eur Urol; 2005 Dec; 48(6):1031-41. PubMed ID: 16054748
[TBL] [Abstract][Full Text] [Related]
37. Clinical applications of molecular biomarkers in prostate cancer detection.
Dumache R; Miclea F; Bumblăcilă B; Puiu M
Rev Med Chir Soc Med Nat Iasi; 2010; 114(2):470-5. PubMed ID: 20700989
[TBL] [Abstract][Full Text] [Related]
38. Meanings of prostate-specific antigen testing as narrated by men with localized prostate cancer after primary treatment.
Hedestig O; Sandman PO; Widmark A; Rasmussen BH
Scand J Urol Nephrol; 2008; 42(2):101-9. PubMed ID: 17907052
[TBL] [Abstract][Full Text] [Related]
39. Beyond PSA: utility of novel tumor markers in the setting of elevated PSA.
Lin DW
Urol Oncol; 2009; 27(3):315-21. PubMed ID: 19414121
[TBL] [Abstract][Full Text] [Related]
40. Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies.
Sartor O
J La State Med Soc; 2008; 160(2):99-100. PubMed ID: 18681353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
